Cryo-Cell International Announces ISO 9001:2000 Certification

OLDSMAR, Fla., Nov. 28 /PRNewswire-FirstCall/ -- CRYO-CELL International, Inc. (“CRYO-CELL” or the “Company”), the world’s largest U-Cord(R) stem cell bank, announced today that it has achieved ISO 9001:2000 certification from BSI Americas, Inc., a leading quality management systems registrar.

ISO (International Organization for Standardization) standards are internationally recognized as an effective framework for a quality management system (QMS). To be certified to the standard, companies must implement a QMS that encompasses a broad scope of company operations including staff training, understanding and meeting customer requirements, designing and developing products and services, purchasing materials and supplies, and delivering quality products and services. To achieve coveted ISO standard certification, a company must effectively demonstrate its comprehensive capabilities that reflect the highest standards of client product and service processes.

“CRYO-CELL is extremely proud to have achieved another major milestone with the attainment of our ISO 9001:2000 certification,” stated Mercedes Walton, Chairman & CEO. “This significant accomplishment underscores the Company’s commitment to deliver industry-leading, best-in-class service to our clients worldwide. We believe that this achievement positions CRYO-CELL as the only current Good Manufacturing Practice/Good Tissue Practice (cGMP/cGTP)- compliant private cord blood bank with both ISO certification and AABB accreditation.”

CRYO-CELL began its registration process at the beginning of 2005. The Company joins its global affiliates, CRYO-CELL de Mexico and Asia CRYO-CELL; both companies have previously established ISO certification. As part of the ISO 9001 process, BSI performed on-site assessments, examined the Company’s documented procedures, and audited its overall operations. To determine continued compliance with ISO 9001:2000, BSI will conduct periodically scheduled audits of CRYO-CELL’s business operations. In addition to ISO certification, CRYO-CELL is registered with the FDA; licensed in New York, New Jersey and Maryland (the only states with applicable regulations); and accredited by the AABB.

About CRYO-CELL International, Inc.

Based in Oldsmar, Florida, CRYO-CELL is the world’s largest U-Cord(R) stem cell bank, offering premium-quality, superior value cord blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. In October 2005, CRYO-CELL announced an exclusive license with Plureon Corporation to develop the proprietary methodology to collect, process and cryogenically preserve Plureon Stem Cells (PSCs) collected from placental tissue at the time of birth. CRYO-CELL has exclusive U.S. rights to market the novel stem cell service to expectant parents. With over 100,000 clients, CRYO- CELL is accredited by the AABB and believes the Company is the first private cord blood bank to operate in a newly constructed state-of-the-art current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility, well in advance of newly established Food and Drug Administration (FDA) regulation. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.CRYO-CELL.com .

About BSI Americas, Inc.

BSI Management Systems is the North and South American hub of BSI, the world’s leading international standards, testing, registration and certification organization. Founded in 1901, BSI has issued more than 35,500 registrations in over 90 countries. As the world’s first national standards body, and a founding member of the International Organization for Standardization (ISO), BSI facilitated and published the first commercial standards to address quality management systems, environmental management systems, occupational health and safety management systems, and project management. Since then more than 112 “Global 500" companies have chosen BSI as their preferred ISO 9000, QS-9000, ISO 14000, TickIT, or EMAS registrar. http://www.bsiamericas.com

Forward-Looking Statement

Statements wherein the terms “believes,” “intends,” “projects” or “expects” as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company’s business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company’s business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward- looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.

CRYO-CELL International, Inc.

CONTACT: Investors, Francesca DeMartino, +1-646-536-7024, orfdemartino@theruthgroup.com, or Media, Janine McCargo, +1-646-536-7033, orjmccargo@theruthgroup.com, both of The Ruth Group, for CRYO-CELL

MORE ON THIS TOPIC